Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
AstraZeneca
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Corcept Therapeutics
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
Immatics US, Inc.
Parabilis Medicines, Inc.
Hospital Universitari de Bellvitge
Revolution Medicines, Inc.
Conjupro Biotherapeutics, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Epsilogen Ltd
AbbVie
Conjupro Biotherapeutics, Inc.
University Hospital, Brest
Imperial College London
Colorado State University
ZIWIG
Memorial Sloan Kettering Cancer Center
Avera McKennan Hospital & University Health Center